The Outcomes of Concomitant Radiation Plus Temozolomide ... - NCI

116
The Outcomes of Concomitant Radiation Plus Temozolomide
substantially better survival rates than patients
who had a biopsy only. These prognostic factors
observed in our patient population under
evaluation were in agreement with the report
published by Stupp, et al. [43].
In conclusion, this is the first report of results
of concomitant RT plus TMZ followed by
adjuvant TMZ therapy in the treatment of HGG
in Clinical Oncology Department, Tanta
University Hospital, Faculty of Medicine, Tanta
University, Egypt. This study demonstrated
concomitant RT plus TMZ followed by adjuvant
TMZ therapy, is a promising regimen for
patients with HGG and we propose concomitant
RT plus TMZ followed by adjuvant TMZ
therapy as an alternative approach with tolerable
toxicities for patients with WHO grade III
gliomas, as well as for those with glioblastoma,
nevertheless, the challenge remains to improve
clinical outcomes further. To confirm this, a
multicenter, meta-analysis and a randomized
trial with a large number of patients are required
in the near future. Many questions remain
unanswered regarding the applications of this
regimen to lower grade gliomas and the optimal
combination of radiotherapy and temozolomide.
REFERENCES
1- Wen PY, Kesari S. Malignant Gliomas in Adults.
NEJM. 2008, 359: 492-507.
2- Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller
BA, Clegg LX, et al. (eds). SEER Cancer Statistics.
2001, 1973-1998. Bethesda, MD, National Cancer
Institute.
3- Kleihues P, Burger PC, Scheithauer BW. The new
WHO classification of brain tumours. Brain Pathol.
1993, 3: 255-68.
4- Pichlmeier U, Bink A, Schackert G, Stummer W, the
ALA Glioma Study Group. Resection and survival in
glioblastoma multiforme: An RTOG recursive
partitioning analysis of ALA study patients. Neurooncol.
2008, 10(6): 1025-34.
5- Sigmond J, Honeywell RJ, Postma TJ, Dirven CMF,
de Lange SM, van der Born K, et al. Gemcitabine
uptake in glioblastoma multiforme: potential as a
radiosensitizer. Ann Oncol. 2009, 20: 182- 7.
6- Vredenburgh JJ, Desjardins A, Reardon DA, Friedman
HS. Experience with irinotecan for the treatment of
malignant glioma. Neuro Oncol. 2009, 11: 80-91.
7- Stupp R, Hegi ME, van den Bent MJ, Mason WP,
Weller M, Mirimanoff RO, et al. Changing paradigmsan
update on the multidisciplinary management of
malignant glioma. Oncologist. 2006, 11(2): 165-80.
8- Gilbert MR. New treatments for malignant gliomas:
careful evaluation and cautious optimism required.
Ann Intern Med. 2006, 144 (5): 371-3.
9- ReardonDA, Rich JN, Friedman HS, Bigner DD.
Recent Advances in the Treatment of Malignant
Astrocytoma. J. Clin. Oncol. 2006, 24 (8): 1253-65.
10- Attenello FJ, Mukherjee D, Datoo G, McGirt MJ,
Bohan E, Weingart JD, et al. Use of Gliadel (BCNU)
Wafer in the Surgical Treatment of Malignant Glioma:
A 10-Year Institutional Experience. Ann. Surg. Oncol.
2008, 15: 2887-93.
11- Galanis E, Buckner J. Chemotherapy for high-grade
gliomas. Br J Cancer. 2000, 82: 1371-80.
12- Levin V, Leibel S, Gutin P. Neoplasms of the central
nervous system, in DeVita V Jr, Hellman S, Rosenberg
S (eds): Cancer: Principles and Practice of Oncology.
Philadelphia, PA, Lippincott-Raven. 1997, pp 2022-82.
13- DeAngelis LM. Brain tumors. N Engl J Med. 2001,
344: 114-23.
14- Buckner JC. Factors influencing survival in highgrade
gliomas. Semin Oncol. 2003, 30 (19): 10-14.
15- Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein
AS, Fischbach AJ, et al. Recursive partitioning analysis
of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer
Inst. 1993, 85: 704-10.
16- Walker MD, Alexander E Jr, Hunt WE, MacCarty CS,
Mahaley MS Jr, Mealey J Jr, et al. Evaluation of
BCNU and/or radiotherapy in the treatment of
anaplastic gliomas: a cooperative clinical trial. J
Neurosurg. 1978, 49: 333-43.
17- Walker MD, Green SB, Byar DP, Alexander E,
Batzdorf U, Brooks WH, et al. Randomized
comparisons of radiotherapy and nitrosoureas for the
treatment of malignant glioma after surgery. N Engl
J Med. 1980, 303 (23): 1323-29.
18- Medical Research Council Brain Tumor Working
Party. Randomized trial of procarbazine, lomustine,
and vincristine in the adjuvant treatment of high-grade
astrocytoma: a Medical Research Council trial. J Clin
Oncol. 2001, 19: 509-18.
19- Shapiro WR, Green SB, Burger PC, Mahaley MS Jr,
Selker RG, VanGilder JC, et al. Randomized trial of
three chemotherapy regimens and two radiotherapy
regimens and two radiotherapy regimens in postoperative
treatment of malignant glioma: Brain Tumor Cooperative
Group trial 8001. J Neurosurg. 1989, 71: 1-9.
20- Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-
Tamayo R, Kramer S, et al. Comparison of
postoperative radiotherapy and combined postoperative
radiotherapy and chemotherapy in the multidisciplinary
management of malignant gliomas: a joint Radiation
Therapy Oncology Group and Eastern Cooperative
Oncology Group study. Cancer. 1983, 52 (6): 997-
1007.
21- Green SB, Byar DP, Walker MD, Pistenmaa DA,
Alexander E Jr, Batzdorf U, et al. Comparisons of